References
1. Kyriakidis NC, López-Cortés A, González EV, Grimaldos AB, Prado EO.
SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3
candidates. NPJ Vaccines. 2021 Feb 22;6(1):28. doi:
10.1038/s41541-021-00292-w.
2. Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK,
Angus B, Baillie VL, Barnabas SL, Bhorat QE, Bibi S, Briner C, Cicconi
P, Collins AM, Colin-Jones R, Cutland CL, Darton TC, Dheda K, Duncan
CJA, Emary KRW, Ewer KJ, Fairlie L, Faust SN, Feng S, Ferreira DM, Finn
A, Goodman AL, Green CM, Green CA, Heath PT, Hill C, Hill H, Hirsch I,
Hodgson SHC, Izu A, Jackson S, Jenkin D, Joe CCD, Kerridge S, Koen A,
Kwatra G, Lazarus R, Lawrie AM, Lelliott A, Libri V, Lillie PJ, Mallory
R, Mendes AVA, Milan EP, Minassian AM, McGregor A, Morrison H, Mujadidi
YF, Nana A, O’Reilly PJ, Padayachee SD, Pittella A, Plested E, Pollock
KM, Ramasamy MN, Rhead S, Schwarzbold AV, Singh N, Smith A, Song R,
Snape MD, Sprinz E, Sutherland RK, Tarrant R, Thomson EC, Török ME,
Toshner M, Turner DPJ, Vekemans J, Villafana TL, Watson MEE, Williams
CJ, Douglas AD, Hill AVS, Lambe T, Gilbert SC, Pollard AJ; Oxford COVID
Vaccine Trial Group. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine
(AZD1222) against SARS-CoV-2: an interim analysis of four randomised
controlled trials in Brazil, South Africa, and the UK. Lancet. 2021 Jan
9;397(10269):99-111. doi: 10.1016/S0140-6736(20)32661-1.
3. Voysey M, Costa Clemens SA, Madhi SA, Weckx LY, Folegatti PM, Aley
PK, Angus B, Baillie VL, Barnabas SL, Bhorat QE, Bibi S, Briner C,
Cicconi P, Clutterbuck EA, Collins AM, Cutland CL, Darton TC, Dheda K,
Dold C, Duncan CJA, Emary KRW, Ewer KJ, Flaxman A, Fairlie L, Faust SN,
Feng S, Ferreira DM, Finn A, Galiza E, Goodman AL, Green CM, Green CA,
Greenland M, Hill C, Hill HC, Hirsch I, Izu A, Jenkin D, Joe CCD,
Kerridge S, Koen A, Kwatra G, Lazarus R, Libri V, Lillie PJ, Marchevsky
NG, Marshall RP, Mendes AVA, Milan EP, Minassian AM, McGregor A,
Mujadidi YF, Nana A, Padayachee SD, Phillips DJ, Pittella A, Plested E,
Pollock KM, Ramasamy MN, Ritchie AJ, Robinson H, Schwarzbold AV, Smith
A, Song R, Snape MD, Sprinz E, Sutherland RK, Thomson EC, Török ME,
Toshner M, Turner DPJ, Vekemans J, Villafana TL, White T, Williams CJ,
Douglas AD, Hill AVS, Lambe T, Gilbert SC, Pollard AJ; Oxford COVID
Vaccine Trial Group. Single-dose administration and the influence of the
timing of the booster dose on immunogenicity and efficacy of ChAdOx1
nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials.
Lancet. 2021 Mar 6;397(10277):881-891. doi:
10.1016/S0140-6736(21)00432-3.
4. Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S,
Belij-Rammerstorfer S, Bellamy D, Bibi S, Bittaye M, Clutterbuck EA,
Dold C, Faust SN, Finn A, Flaxman AL, Hallis B, Heath P, Jenkin D,
Lazarus R, Makinson R, Minassian AM, Pollock KM, Ramasamy M, Robinson H,
Snape M, Tarrant R, Voysey M, Green C, Douglas AD, Hill AVS, Lambe T,
Gilbert SC, Pollard AJ; Oxford COVID Vaccine Trial Group. Safety and
immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a
preliminary report of a phase 1/2, single-blind, randomised controlled
trial. Lancet. 2020 Aug 15;396(10249):467-478. doi:
10.1016/S0140-6736(20)31604-4.
5. Ramasamy MN, Minassian AM, Ewer KJ, Flaxman AL, Folegatti PM, Owens
DR, Voysey M, Aley PK, Angus B, Babbage G, Belij-Rammerstorfer S, Berry
L, Bibi S, Bittaye M, Cathie K, Chappell H, Charlton S, Cicconi P,
Clutterbuck EA, Colin-Jones R, Dold C, Emary KRW, Fedosyuk S, Fuskova M,
Gbesemete D, Green C, Hallis B, Hou MM, Jenkin D, Joe CCD, Kelly EJ,
Kerridge S, Lawrie AM, Lelliott A, Lwin MN, Makinson R, Marchevsky NG,
Mujadidi Y, Munro APS, Pacurar M, Plested E, Rand J, Rawlinson T, Rhead
S, Robinson H, Ritchie AJ, Ross-Russell AL, Saich S, Singh N, Smith CC,
Snape MD, Song R, Tarrant R, Themistocleous Y, Thomas KM, Villafana TL,
Warren SC, Watson MEE, Douglas AD, Hill AVS, Lambe T, Gilbert SC, Faust
SN, Pollard AJ; Oxford COVID Vaccine Trial Group. Safety and
immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost
regimen in young and old adults (COV002): a single-blind, randomised,
controlled, phase 2/3 trial. Lancet. 2021 Dec 19;396(10267):1979-1993.
doi: 10.1016/S0140-6736(20)32466-1.
6. van Doremalen N, Lambe T, Spencer A, Belij-Rammerstorfer S,
Purushotham JN, Port JR, Avanzato VA, Bushmaker T, Flaxman A, Ulaszewska
M, Feldmann F, Allen ER, Sharpe H, Schulz J, Holbrook M, Okumura A,
Meade-White K, Pérez-Pérez L, Edwards NJ, Wright D, Bissett C, Gilbride
C, Williamson BN, Rosenke R, Long D, Ishwarbhai A, Kailath R, Rose L,
Morris S, Powers C, Lovaglio J, Hanley PW, Scott D, Saturday G, de Wit
E, Gilbert SC, Munster VJ. ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2
pneumonia in rhesus macaques. Nature. 2020 Oct;586(7830):578-582. doi:
10.1038/s41586-020-2608-y.
7. van Doremalen N, Haddock E, Feldmann F, Meade-White K, Bushmaker T,
Fischer RJ, Okumura A, Hanley PW, Saturday G, Edwards NJ, Clark MHA,
Lambe T, Gilbert SC, Munster VJ. A single dose of ChAdOx1 MERS provides
protective immunity in rhesus macaques. Sci Adv. 2020 Jun
10;6(24):eaba8399. doi: 10.1126/sciadv.aba8399. 8. Leung K, Shum MH,
Leung GM, Lam TT, Wu JT. Early transmissibility assessment of the N501Y
mutant strains of SARS-CoV-2 in the United Kingdom, October to November
2020. Euro Surveill. 2021 Jan;26(1):2002106. doi:
10.2807/1560-7917.ES.2020.26.1.2002106.
8. Leung K, Shum MH, Leung GM, Lam TT, Wu JT. Early transmissibility
assessment of the N501Y mutant strains of SARS-CoV-2 in the United
Kingdom, October to November 2020. Euro Surveill. 2021
Jan;26(1):2002106. doi: 10.2807/1560-7917.ES.2020.26.1.2002106.
9. Shen X, Tang H, McDanal C, Wagh K, Fischer W, Theiler J, Yoon H, Li
D, Haynes BF, Sanders KO, Gnanakaran S, Hengartner N, Pajon R, Smith G,
Glenn GM, Korber B, Montefiori DC. SARS-CoV-2 variant B.1.1.7 is
susceptible to neutralizing antibodies elicited by ancestral spike
vaccines. Cell Host Microbe. 2021 Mar 5:S1931-3128(21)00102-5. doi:
10.1016/j.chom.2021.03.002.
10. Davies NG, Abbott S, Barnard RC, Jarvis CI, Kucharski AJ, Munday JD,
Pearson CAB, Russell TW, Tully DC, Washburne AD, Wenseleers T, Gimma A,
Waites W, Wong KLM, van Zandvoort K, Silverman JD; CMMID COVID-19
Working Group; COVID-19 Genomics UK (COG-UK) Consortium, Diaz-Ordaz K,
Keogh R, Eggo RM, Funk S, Jit M, Atkins KE, Edmunds WJ. Estimated
transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England.
Science. 2021 Mar 3:eabg3055. doi: 10.1126/science.abg3055.
11. Wang P, Nair MS, Liu L, Iketani S, Luo Y, Guo Y, Wang M, Yu J, Zhang
B, Kwong PD, Graham BS, Mascola JR, Chang JY, Yin MT, Sobieszczyk M,
Kyratsous CA, Shapiro L, Sheng Z, Huang Y, Ho DD. Antibody Resistance of
SARS-CoV-2 Variants B.1.351 and B.1.1.7. Nature. 2021 Mar 8. doi:
10.1038/s41586-021-03398-2.
12. Wise J. Covid-19: The E484K mutation and the risks it poses. BMJ.
2021 Feb 5;372:n359. doi: 10.1136/bmj.n359.
13. Chen RE, Zhang X, Case JB, Winkler ES, Liu Y, VanBlargan LA, Liu J,
Errico JM, Xie X, Suryadevara N, Gilchuk P, Zost SJ, Tahan S, Droit L,
Turner JS, Kim W, Schmitz AJ, Thapa M, Wang D, Boon ACM, Presti RM,
O’Halloran JA, Kim AHJ, Deepak P, Pinto D, Fremont DH, Crowe JE Jr,
Corti D, Virgin HW, Ellebedy AH, Shi PY, Diamond MS. Resistance of
SARS-CoV-2 variants to neutralization by monoclonal and serum-derived
polyclonal antibodies. Nat Med. 2021 Mar 4. doi:
10.1038/s41591-021-01294-w.
14. Zhou D, Dejnirattisai W, Supasa P, Liu C, Mentzer AJ, Ginn HM, Zhao
Y, Duyvesteyn HME, Tuekprakhon A, Nutalai R, Wang B, Paesen GC,
Lopez-Camacho C, Slon-Campos J, Hallis B, Coombes N, Bewley K, Charlton
S, Walter TS, Skelly D, Lumley SF, Dold C, Levin R, Dong T, Pollard AJ,
Knight JC, Crook D, Lambe T, Clutterbuck E, Bibi S, Flaxman A, Bittaye
M, Belij-Rammerstorfer S, Gilbert S, James W, Carroll MW, Klenerman P,
Barnes E, Dunachie SJ, Fry EE, Mongkolsapaya J, Ren J, Stuart DI,
Screaton GR. Evidence of escape of SARS-CoV-2 variant B.1.351 from
natural and vaccine-induced sera. Cell. 2021 Feb
23:S0092-8674(21)00226-9. doi: 10.1016/j.cell.2021.02.037.
15. Wibmer CK, Ayres F, Hermanus T, Madzivhandila M, Kgagudi P,
Oosthuysen B, Lambson BE, de Oliveira T, Vermeulen M, van der Berg K,
Rossouw T, Boswell M, Ueckermann V, Meiring S, von Gottberg A, Cohen C,
Morris L, Bhiman JN, Moore PL. SARS-CoV-2 501Y.V2 escapes neutralization
by South African COVID-19 donor plasma. Nat Med. 2021 Mar 2. doi:
10.1038/s41591-021-01285-x.
16. Madhi SA, Baillie V, Cutland CL, Voysey M, Koen AL, Fairlie L,
Padayachee SD, Dheda K, Barnabas SL, Bhorat QE, Briner C, Kwatra G,
Ahmed K, Aley P, Bhikha S, Bhiman JN, Bhorat AE, du Plessis J, Esmail A,
Groenewald M, Horne E, Hwa SH, Jose A, Lambe T, Laubscher M, Malahleha
M, Masenya M, Masilela M, McKenzie S, Molapo K, Moultrie A, Oelofse S,
Patel F, Pillay S, Rhead S, Rodel H, Rossouw L, Taoushanis C, Tegally H,
Thombrayil A, van Eck S, Wibmer CK, Durham NM, Kelly EJ, Villafana TL,
Gilbert S, Pollard AJ, de Oliveira T, Moore PL, Sigal A, Izu A; NGS-SA
Group Wits–VIDA COVID Group. Efficacy of the ChAdOx1 nCoV-19 Covid-19
Vaccine against the B.1.351 Variant. N Engl J Med. 2021 Mar 16. doi:
10.1056/NEJMoa2102214.
17. Thomson EC, Rosen LE, Shepherd JG, Spreafico R, da Silva Filipe A,
Wojcechowskyj JA, Davis C, Piccoli L, Pascall DJ, Dillen J, Lytras S,
Czudnochowski N, Shah R, Meury M, Jesudason N, De Marco A, Li K, Bassi
J, O’Toole A, Pinto D, Colquhoun RM, Culap K, Jackson B, Zatta F,
Rambaut A, Jaconi S, Sreenu VB, Nix J, Zhang I, Jarrett RF, Glass WG,
Beltramello M, Nomikou K, Pizzuto M, Tong L, Cameroni E, Croll TI,
Johnson N, Di Iulio J, Wickenhagen A, Ceschi A, Harbison AM, Mair D,
Ferrari P, Smollett K, Sallusto F, Carmichael S, Garzoni C, Nichols J,
Galli M, Hughes J, Riva A, Ho A, Schiuma M, Semple MG, Openshaw PJM,
Fadda E, Baillie JK, Chodera JD; ISARIC4C Investigators; COVID-19
Genomics UK (COG-UK) Consortium, Rihn SJ, Lycett SJ, Virgin HW, Telenti
A, Corti D, Robertson DL, Snell G. Circulating SARS-CoV-2 spike N439K
variants maintain fitness while evading antibody-mediated immunity.
Cell. 2021 Mar 4;184(5):1171-1187.e20. doi: 10.1016/j.cell.2021.01.037.
Epub 2021 Jan 28.
18. Emary KRW, Golubchik T, Aley PK, Ariani CV, Angus B, Bibi S, Blane
B, Bonsall D, Cicconi P, Charlton S, Clutterbuck EA, Collins AM, Cox T,
Darton TC, Dold C, Douglas AD, Duncan CJA, Ewer KJ, Flaxman AL, Faust
SN, Ferreira DM, Feng S, Finn A, Folegatti PM, Fuskova M, Galiza E,
Goodman AL, Green CM, Green CA, Greenland M, Hallis B, Heath PT, Hay J,
Hill HC, Jenkin D, Kerridge S, Lazarus R, Libri V, Lillie PJ, Ludden C,
Marchevsky NG, Minassian AM, McGregor AC, Mujadidi YF, Phillips DJ,
Plested E, Pollock KM, Robinson H, Smith A, Song R, Snape MD, Sutherland
RK, Thomson EC, Toshner M, Turner DPJ, Vekemans J, Villafana TL,
Williams CJ, Hill AVS, Lambe T, Gilbert SC, Voysey M, Ramasamy MN,
Pollard AJ; COVID-19 Genomics UK consortium; AMPHEUS Project; Oxford
COVID-19 Vaccine Trial Group. Efficacy of ChAdOx1 nCoV-19 (AZD1222)
vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an
exploratory analysis of a randomised controlled trial. Lancet. 2021 Apr
10;397(10282):1351-1362. doi: 10.1016/S0140-6736(21)00628-0.
19. Pritchard Emma, Philippa C. Matthews, Nicole Stoesser, David W.
Eyre, Owen Gethings, Karina-Doris Vihta, Joel Jones, Thomas House,
Harper VanSteenHouse, Iain Bell, John I Bell, John N Newton, Jeremy
Farrar, Ian Diamond, Emma Rourke, Ruth Studley, Derrick Crook, Tim Peto,
A. Sarah Walker, Koen B. Pouwels, Coronavirus Infection Survey team.
Impact of vaccination on SARS-CoV-2 cases in the community: a
population-based study using the UK’s COVID-19 Infection Survey. medRxiv
2021.04.22.21255913; doi:https://doi.org/10.1101/2021.04.22.21255913
(Posted April 23, 2021).
20. Chambers J. Chile sees Covid surge despite vaccination success.
Available online:https://www.bbc.com/news/world-latin-america-56731801(accessed on 16 April 2021)
21. Lee WS, Wheatley AK, Kent SJ, DeKosky BJ. Antibody-dependent
enhancement and SARS-CoV-2 vaccines and therapies. Nat Microbiol. 2020
Oct;5(10):1185-1191. doi: 10.1038/s41564-020-00789-5.
22. Francis ME, King ML, Kelvin AA. Back to the Future for Influenza
Preimmunity-Looking Back at Influenza Virus History to Infer the Outcome
of Future Infections. Viruses. 2019 Jan 30;11(2):122. doi:
10.3390/v11020122.
23. Roxby P. Are Covid patients getting younger? Available online:https://www.bbc.com/news/health-55586994(accessed on 11 January 2021)
24. Volz E, Mishra S, Chand M, Barrett JC, Johnson R, Geidelberg L, et
al. Transmission of SARS-CoV-2 lineage B.1.1.7 in England: insights from
linking epidemiological and genetic data. medRxiv 20249034
[Preprint]. 2021 Jan 04 [cited 2021 Jan 04]. Available from:
https://doi.org/10.1101/2020.12.30.20249034
25. Challen R, Brooks-Pollock E, Read JM, Dyson L, Tsaneva-Atanasova K,
Danon L. Risk of mortality in patients infected with SARS-CoV-2 variant
of concern 202012/1: matched cohort study. BMJ. 2021 Mar 9;372:n579.
doi: 10.1136/bmj.n579.
26. Davies NG, Jarvis CI; CMMID COVID-19 Working Group, Edmunds WJ,
Jewell NP, Diaz-Ordaz K, Keogh RH. Increased mortality in
community-tested cases of SARS-CoV-2 lineage B.1.1.7. Nature. 2021 Mar
15. doi: 10.1038/s41586-021-03426-1.
27. Zamai L. Upregulation of the Renin-Angiotensin System Pathways and
SARS-CoV-2 Infection: The Rationale for the Administration of
Zinc-Chelating Agents in COVID-19 Patients. Cells. 2021 Feb
27;10(3):506. doi: 10.3390/cells10030506.
28. Zamai L. The Yin and Yang of ACE/ACE2 Pathways: The Rationale for
the Use of Renin-Angiotensin System Inhibitors in COVID-19 Patients.
Cells. 2020 Jul 16;9(7):1704. doi: 10.3390/cells9071704.
29. Yuan S, Wang R, Chan JF, Zhang AJ, Cheng T, Chik KK, Ye ZW, Wang S,
Lee AC, Jin L, Li H, Jin DY, Yuen KY, Sun H. Metallodrug ranitidine
bismuth citrate suppresses SARS-CoV-2 replication and relieves
virus-associated pneumonia in Syrian hamsters. Nat Microbiol. 2020
Nov;5(11):1439-1448. doi: 10.1038/s41564-020-00802-x.
30. Yuan S, Yin X, Meng X, Chan JF, Ye ZW, Riva L, Pache L, Chan CC, Lai
PM, Chan CC, Poon VK, Lee AC, Matsunaga N, Pu Y, Yuen CK, Cao J, Liang
R, Tang K, Sheng L, Du Y, Xu W, Lau CY, Sit KY, Au WK, Wang R, Zhang YY,
Tang YD, Clausen TM, Pihl J, Oh J, Sze KH, Zhang AJ, Chu H, Kok KH, Wang
D, Cai XH, Esko JD, Hung IF, Li RA, Chen H, Sun H, Jin DY, Sun R, Chanda
SK, Yuen KY. Clofazimine broadly inhibits coronaviruses including
SARS-CoV-2. Nature. 2021 Mar 16. doi: 10.1038/s41586-021-03431-4.
31. Haga S, Yamamoto N, Nakai-Murakami C, Osawa Y, Tokunaga K, Sata T,
Yamamoto N, Sasazuki T, Ishizaka Y. Modulation of TNF-alpha-converting
enzyme by the spike protein of SARS-CoV and ACE2 induces TNF-alpha
production and facilitates viral entry. Proc Natl Acad Sci U S A. 2008
Jun 3;105(22):7809-14. doi: 10.1073/pnas.0711241105.
32. Patel SK, Juno JA, Lee WS, Wragg KM, Hogarth PM, Kent SJ, Burrell
LM. Plasma ACE2 activity is persistently elevated following SARS-CoV-2
infection: implications for COVID-19 pathogenesis and consequences. Eur
Respir J. 2021 Jan 21:2003730. doi: 10.1183/13993003.03730-2020.
33. McCarthy KR, Rennick LJ, Nambulli S, Robinson-McCarthy LR, Bain WG,
Haidar G, Duprex WP. Recurrent deletions in the SARS-CoV-2 spike
glycoprotein drive antibody escape. Science. 2021 Mar
12;371(6534):1139-1142. doi: 10.1126/science.abf6950.
34. Haga S, Nagata N, Okamura T, Yamamoto N, Sata T, Yamamoto N,
Sasazuki T, Ishizaka Y. TACE antagonists blocking ACE2 shedding caused
by the spike protein of SARS-CoV are candidate antiviral compounds.
Antiviral Res. 2010 Mar;85(3):551-5. doi:
10.1016/j.antiviral.2009.12.001.